Printer Friendly

BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY

 CAMBRIDGE, Mass., Aug. 20 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) today announced a realignment of responsibilities among several of its senior executives.
 In announcing the changes of assignments, Jim Vincent, Biogen's chief executive officer, said "Biogen's next challenge is the transition from a research and development organization to an operating company. To achieve this goal, we are realigning our management structure to maximize the unique strengths of our senior executive team."
 Irvin D. Smith, Ph.D., was appointed vice president, QA/QC and Drug Development, with responsibility for the company's quality control, quality assurance and N.D.A. filing activities. Most recently, Smith was general manager of Bioferon, Biogen's joint venture in Germany.
 Kenneth M. Bate was named vice president-marketing and sales. He will be responsible for marketing and business development, as well as for establishing Biogen's sales and sales support organization in preparation for the launch of the company's first proprietary drugs. Bate has been vice president-finance and chief financial officer since 1990.
 Lawrence S. Daniels has been named vice president-strategic planning, a new position. He will be in charge of strategic planning for the company and will be responsible for developing new approaches to business planning requirements. He has been vice president-marketing since 1991.
 Timothy M. Kish has been promoted to the position of vice president- Finance and chief financial officer. He has served as corporate controller since 1986.
 Vincent also noted that Smith's position was interim in nature and will last up to two years, after which he will retire from Biogen.
 Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and other viruses and cancers.
 -0- 8/20/93
 /CONTACT: Kathryn R. Bloom, director of communcations, 617-252-9851, or Amy S. Hedison, director of investor relations, 617-252-9873, both of Biogen, Inc./
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER

JL-DJ -- NE001 -- 4660 08/20/93 10:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 20, 1993
Words:368
Previous Article:PARAMOUNT PROMOTES LISA DIMARZIO TO VICE PRESIDENT, PROMOTIONS
Next Article:RECORD EARNINGS FOR NORTHBAY FINANCIAL
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters